{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:51:32Z","timestamp":1790553092906,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR071653"],"award-info":[{"award-number":["R01AR071653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can occur with or without underlying systemic lupus erythematosus (SLE) and often has a profoundly negative impact on patient quality of life. There is substantial need for new and more effective therapies to treat CLE. CLE has a multifactorial pathogenesis that involves several key immune cells and pathways, including abnormalities in innate (e.g., type 1 interferon pathways) and adaptive immune responses (e.g., B and T cell autoreactivity), presenting multiple opportunities for more targeted therapies that do not require immunosuppression. Here we review several emerging therapies and their efficacy in CLE. Anifrolumab and belimumab have both been approved for the treatment of SLE in recent years, and clinical trial evidence suggests some forms of CLE may improve with these agents. Therapies currently in development that are being evaluated with CLE-specific outcome measures include BIIB059 and VIB7734, which target plasmacytoid dendritic cells (pDCs), and iberdomide, a cereblon modulator. These novel therapies all have previously demonstrated clinical benefit in some forms of CLE. Other therapies which target molecules believed to play a role in CLE pathogenesis, such as Janus kinases (JAKs), spleen tyrosine kinase (SYK), interferon \u03b3 (IFN\u03b3), IL-12, and IL-23, have been evaluated in lupus clinical trials with skin-specific outcomes but failed to meet their primary endpoints.<\/jats:p>","DOI":"10.3389\/fmed.2022.968323","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T07:09:21Z","timestamp":1657523361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Emerging Therapies in Cutaneous Lupus Erythematosus"],"prefix":"10.3389","volume":"9","author":[{"given":"Grant","family":"Sprow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2133.1996.tb01495.x","article-title":"Cutaneous manifestations of systemic lupus erythematosus","volume":"135","author":"Yell","year":"1996","journal-title":"Br J Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jaad.2010.02.008","article-title":"Quality of life in cutaneous lupus erythematosus","volume":"64","author":"Klein","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","article-title":"Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus","volume":"147","author":"Klein","year":"2011","journal-title":"Arch Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e000430","DOI":"10.1136\/lupus-2020-000430","article-title":"Candidate drug replacements for quinacrine in cutaneous lupus erythematosus","volume":"7","author":"Yan","year":"2020","journal-title":"Lupus Sci Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.berh.2017.10.003","article-title":"Role of interferons in SLE","volume":"31","author":"Bengtsson","year":"2017","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemic immune\u2013based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Care Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/0961203316682097","article-title":"Belimumab for the treatment of recalcitrant cutaneous lupus","volume":"26","author":"Vashisht","year":"2017","journal-title":"Lupus."},{"key":"B16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.autrev.2017.02.005","article-title":"Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus","volume":"16","author":"Parodis","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B17","first-page":"81","article-title":"Focus: skin: cutaneous lupus erythematosus: current and future pathogenesis-directed therapies","volume":"93","author":"Little","year":"2020","journal-title":"Yale J Biol Med."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.5743","article-title":"OP0193 BIIB059, a humanized monoclonal antibody targeting BDCA2 on plasmacytoid dendritic cells (pDC), shows dose-related efficacy in the phase 2 LILAC study in patients (pts) with active cutaneous lupus erythematosus (CLE)","author":"Werth","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"14158","DOI":"10.3390\/ijms160614158","article-title":"A plasmacytoid dendritic cells-type I interferon axis is critically implicated in the pathogenesis of systemic lupus erythematosus","volume":"16","author":"Kim","year":"2015","journal-title":"Int J Mol Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"eabf8442","DOI":"10.1126\/scitranslmed.abf8442","article-title":"Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1002341","DOI":"10.1371\/journal.pgen.1002341","article-title":"Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus","volume":"7","author":"Cunninghame Graham","year":"2011","journal-title":"PLoS Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia."},{"key":"B24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu","year":"2013","journal-title":"Leuk Lymphoma."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e000581","DOI":"10.1136\/lupus-2021-000581","article-title":"Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study","volume":"9","author":"Furie","year":"2022","journal-title":"Lupus Sci Med."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222212.","article-title":"Biological impact of iberdomide in patients with active systemic lupus erythematosus","author":"Lipsky","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/annrheumdis-2021-eular.2181","article-title":"Op0132 effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: results of a 24-week, placebo-controlled, phase 2 study","volume":"80","author":"Werth","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov."},{"key":"B32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/art.39950","article-title":"Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab","volume":"69","author":"Hoffman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fimmu.2020.00344","article-title":"Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions","volume":"11","author":"Fetter","year":"2020","journal-title":"Front Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/bjd.17344","article-title":"A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus","volume":"180","author":"Werth","year":"2019","journal-title":"Br J Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/exd.12986","article-title":"Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients","volume":"25","author":"Braegelmann","year":"2016","journal-title":"Exp Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"93","author":"Werth","year":"2021","journal-title":"Rheumatology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/exd.14253","article-title":"Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: a double-blind Phase Ib study","volume":"30","author":"Walker","year":"2021","journal-title":"Exp Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/bjd.16337","article-title":"Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus","volume":"178","author":"Presto","year":"2018","journal-title":"Br J Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s11095-014-1492-2","article-title":"Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-\u03b3 IgG1 monoclonal antibody, in patients with systemic lupus erythematosus","volume":"32","author":"Chen","year":"2015","journal-title":"Pharm Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1001\/archderm.136.12.1497","article-title":"Detection of type 1 cytokines in discoid lupus erythematosus","volume":"136","author":"Toro","year":"2000","journal-title":"Arch Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/art.39248","article-title":"Blockade of interferon-\u03b3 normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus","volume":"67","author":"Welcher","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B44","article-title":"A phase I single-dose crossover study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of AMG 811 (anti-IFN-gamma) in subjects with discoid lupus erythematosus","author":"Werth","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/annrheumdis-2015-eular.2916","article-title":"THU0389 a multiple dose study of AMG 811 (Anti-IFN-Gamma) in subjects with systemic lupus erythematosus and active nephritis","volume":"74","author":"Martin","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/art.40052","article-title":"Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti\u2013interferon-\u03b3 antibody, in patients with discoid lupus erythematosus","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4049\/jimmunol.1700418","article-title":"IL-23 limits the production of IL-2 and promotes autoimmunity in lupus","volume":"199","author":"Dai","year":"2017","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/icb.2017.53","article-title":"Cytokines in systemic lupus erythematosus: far beyond Th1\/Th2 dualism lupus: cytokine profiles","volume":"95","author":"Guimar\u00e3es","year":"2017","journal-title":"Immunol Cell Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3899\/jrheum.210805","article-title":"Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase II open-label extension study","volume":"49","author":"van Vollenhoven","year":"2022","journal-title":"J Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.968323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T07:09:25Z","timestamp":1657523365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.968323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":50,"alternative-id":["10.3389\/fmed.2022.968323"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.968323","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"article-number":"968323"}}